J&J posts a sol­id round of pos­i­tive ear­ly da­ta for their BC­MA/CD3 bis­pe­cif­ic teclis­tam­ab, high­light­ing block­buster ex­pec­ta­tions

J&J’s on­col­o­gy R&D team has post­ed promis­ing ear­ly da­ta on one of its block­buster drug can­di­dates in the pipeline.

JNJ-7957, their BC­MA/CD3 bis­pe­cif­ic now called teclis­tam­ab, hit a 67% over­all re­sponse rate among the 12 pa­tients with mul­ti­ple myelo­ma who re­ceived the high­est dose avail­able in their Phase I tri­al. Among those 8 of 12 pa­tients, 3 achieved a com­plete re­sponse, with no vis­i­ble sign of the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER